Monday, August 6, 2001
Share and share alike
If companies were to pool all of their toxicology data from both successful and failed compounds, a significant amount probably could be learned very quickly. But that is unlikely to happen, as knowledge of useful structures is highly valuable proprietary information. Nor are companies likely to share high throughput tox screening technologies, which also are viewed as conferring a competitive advantage. What is more likely to be shared is development of new screening assays and structural information on compounds that have failed in preclinical or clinical studies.
According to James Moe, head of global toxicology, Pharmacia Corp., is willing to share some of its expertise in cardiotoxicity through an initiative by the